Clicky

Monte Rosa Therapeutics, Inc.(GLUE)

Description: Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™, that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.


Keywords: Biotechnology Drug Discovery Machine Learning Proteomics Computational Chemistry

Home Page: www.monterosatx.com

GLUE Technical Analysis

645 Summer Street
Boston, MA 02210
United States
Phone: 617 949 2643


Officers

Name Title
Dr. Markus Warmuth M.D. Pres, CEO & Director
Dr. Owen B. Wallace Ph.D. Chief Scientific Officer
Dr. Filip Janku M.D., Ph.D. Chief Medical Officer
Mr. Ajim A. Tamboli C.F.A. Chief Financial Officer
Ms. Jennifer Champoux Sr. VP of Operations
Dr. Sharon Townson Ph.D. Chief Technology Officer
Mr. Phil Nickson J.D., Ph.D. Gen. Counsel
Dr. John C. Castle Ph.D. Chief Data Scientist
Dr. Jullian G. Jones J.D., M.B.A., Ph.D. Chief Bus. Officer
Dr. Silvia Buonamici Ph.D. Sr. VP of Drug Discovery Biology

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 1.3399
Price-to-Book MRQ: 1.4266
Price-to-Sales TTM: 0
IPO Date: 2021-06-24
Fiscal Year End: December
Full Time Employees: 118
Back to stocks